Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 20Neoplasms 19Colorectal Neoplasms 19Recurrence 17Pancreatic Neoplasms 17Multiple Myeloma 15Advanced Solid Tumors 13Prostatic Neoplasms 12Advanced Solid Tumor 12Stomach Neoplasms 10Ovarian Neoplasms 10Leukemia, Myeloid, Acute 10Carcinoma, Hepatocellular 10Triple Negative Breast Neoplasms 8Neoplasm Metastasis 7Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Lymphoma, Large B-Cell, Diffuse 6Head and Neck Neoplasms 6Glioblastoma 6Urinary Bladder Neoplasms 5Solid Tumors 5Solid Tumor 5Lymphoma, B-Cell 5Lung Neoplasms 5Liver Neoplasms 5Glioma 5Endometrial Neoplasms 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Neurofibromatosis 2 × Clear all
NCT07131722 2026-01-23

Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II

PRG Science & Technology Co., Ltd.

Phase 1/2 Not yet recruiting
25 enrolled
CNS

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡